Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Bradley J. Monk; Jyoti Mayadev; Ana T. Nunes

doi:10.1016/j.gore.2019.100506

Back

Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Journal article

Open access

Peer reviewed

Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Bradley J. Monk, Jyoti Mayadev and Ana T. Nunes

Gynecologic oncology reports, Vol.30, pp.100506-100506

11/01/2019

DOI: https://doi.org/10.1016/j.gore.2019.100506

PMCID: PMC6906726

PMID: 31867430

Abstract

Correspondence

• CALLA (NCT03830866) is a randomized, international, double-blind, placebo-controlled study. • Immunotherapy-naïve patients with adenocarcinoma or cervical carcinoma are being enrolled. • CALLA is one of the largest trials in this patient population.

Files and links (1)

url

https://doi.org/10.1016/j.gore.2019.100506View

Published (Version of record) Open

Metrics

5 Record Views

Details

Title: Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Creators: Bradley J. Monk - The US Oncology Network
Jyoti Mayadev - University of California, San Diego
Ana T. Nunes - AstraZeneca
Publication Details: Gynecologic oncology reports, Vol.30, pp.100506-100506
Publisher: Elsevier
Identifiers: 991005969144102656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article